Voyageur Pharmaceuticals Ltd. (VYYRF)
| Market Cap | 6.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.13M |
| Shares Out | n/a |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0020 |
| Previous Close | 0.0020 |
| Day's Range | 0.0020 - 0.0020 |
| 52-Week Range | 0.0005 - 0.0780 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 24, 2025 |
About Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products in the province of British Columbia, Canada, and the state of Utah. It develops barium, iodine-based APIs, and imaging contrast agents for medical radiology. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada. [Read more]
Full Company ProfileNews
Voyageur Announces Proposed Private Placement
Calgary, Alberta--(Newsfile Corp. - October 17, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Corporation"), is pleased to announce a proposed non-brokered pri...
Voyageur Pharmaceuticals Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - September 25, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") announces that it has granted an aggregate of 600,000...
Voyageur Pharmaceuticals Ltd. Announces Equity Incentive Compensation
Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Uni...
Voyageur Pharmaceuticals Ltd. Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
Voyageur Pharmaceuticals is moving forward with FDA device registrations for the US market. Voyageur Pharmaceuticals is moving forward with FDA device registrations for the US market.
Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product
Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field Voyageur is moving forward with its business plan of becoming...